Dolutegravir-Lamivudine as Dual Therapy in naïve HIV-Infected Patients With Documented M184V Mutation:A Pilot Study

NCT05295394 | Withdrawn Phase 4 DMC

• 1 other identifier: FH-42
• Study Type: interventional
• Target: N/A
• Locations: 1 country
• Sites: 2

Brief Summary

The purpose of this study is to evaluate the antiviral efficacy, safety and tolerability of dual therapy with 3TC and DTG as initial therapy among naïve HIV patients with a documented M184V mutation.

Conditions

HIV-1 Infection

Keywords

HIV-1 naive infected patients; dual therapy; M184V mutation

Outcome Measures

Primary Outcomes (1)

• HIV viral load efficacy at week 48

  the proportion of patients with pVL \< 50 copies/mL at week 48 using the ITT-exposed analysis (FDA snaphot).

  48 weeks

Secondary Outcomes (5)

• HIV viral resistance mutations

  At week 48

• HIV viral load efficacy at week 24

  week 24 and week 36

• immunological response in CD4 cell count

  baseline and week 48

• adverse events

  baseline to 48 weeks

• lipid profile change

  baseline and week 48

Study Arms (1)

single arm

EXPERIMENTAL

dolutegravir 50 mg QD plus lamivudine 300 mg QD

Drug: Dolutegravir plus lamivudine

Interventions

Dolutegravir plus lamivudine DRUG

Dolutegravir 50 mg QD plus lamivudine 300 mg QD

Also known as: dual therapy

single arm

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• ≥18 years of age.
• Documented HIV-1 infection defined as a positive rapid test or ELISA plus a plasma HIV-1 RNA ≥5,000 copies/mL or a reactive western blot.
• Subject has voluntarily signed and dated an informed consent form, approved by an Institutional Review Board (IRB) / Independent Ethics Committee (IEC), after the nature of the study has been explained and the subject has had the opportunity to ask questions. The informed consent must be signed before any study-specific procedures are performed (see Appendix 4).
• Naïve to ARV therapies (previous exposure to ARV drugs \< 10 days).
• Documented M184V mutation associated with resistance to lamivudine in a previous genotypic test (last 3 months), or at screening.
• HIV RNA at screening visit ≥5,000 copies/mL and \<≤100,000 copies/ml
• CD4 ≥200 cells/mL
• Subjects can comply with protocol requirements.
• Subject agrees not to take any medication during the study, including over the counter medicines or herbal preparations, without the approval of the trial physician.
• Subject's general medical condition, in the investigator's opinion, does not interfere with assessments and completion of the study.
• The patient is a male or a female who is not breastfeeding or pregnant.
• A female may be eligible to enter and participate in the study if she:
• is of non-child-bearing potential either defined as post-menopausal (12 months of spontaneous amenorrhea and ≥ 45 years of age) or physically incapable of becoming pregnant with documented tubal ligation, hysterectomy or bilateral oophorectomy or,
• is of child-bearing potential with a negative pregnancy test at both screening and day 1, and, agrees to use one of the highly effective methods of contraception to avoid pregnancy described in Appendix 3.

You may not qualify if:

• Patients will NOT be selected to be part of this study if they meet ANY of the following criteria:
• Alcohol or drug use that might impact on adherence
• Subjects positive for Hepatitis B at screening (+HBsAg), or anticipated need for Hepatitis C virus (HCV) therapy during the study
• Women who are pregnant or breastfeeding, or women who plan to become pregnant in the next 2 years
• interferon, interleukin-2, cytotoxic chemotherapy, Dofetilide (or pilsicainide) or immunosuppressors, antacid drugs containing Ca++ and or Mg++ at study entry
• Grade 4 lab abnormalities
• Primary HIV infection (indeterminate WB or previous negative HIV in the last 6 months
• Opportunistic infection (CDC C category) or other disease and/or clinical condition that, in the investigator's opinion, would compromise the patient's safety or outcome of the study; including malignancy other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, non-invasive cutaneous squamous cell carcinoma, or cervical intraepithelial neoplasia
• Subjects who in the investigator's judgment, poses a significant suicidality risk.
• History or presence of allergy to the study drugs or their components or drugs of their class
• Treatment with any of the following agents within 28 days of screening: radiation therapy; cytotoxic chemotherapeutic agents; any immunomodulators that alter immune responses or treatment with an HIV-1 immunotherapeutic vaccine within 90 days of screening or exposure to an experimental drug or experimental vaccine within either 28 days, 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent, whichever is longer, prior to the first dose of investigational product
• Any acute laboratory abnormality at screening, which, in the opinion of the Investigator, would preclude the subject's participation in the study of an investigational compound;
• Alanine aminotransferase (ALT) \>5 times the upper limit of normal (ULN), or ALT ≥ 3xULN and bilirubin ≥ 1.5xULN (with \>35% direct bilirubin)
• Creatinine clearance of \<50mL/min via Cockroft-Gault method
• Subjects with moderate to severe hepatic impairment (Class B or greater) as determined by Child-Pugh classification

Sponsors & Collaborators

• Pedro Cahn: lead
• ViiV Healthcare: collaborator

Study Sites (2)

Fundacion huesped

CABA, Buenos Aires, C1202ABB, Argentina

Location

CAICI

Rosario, Santa Fe Province, S2000PBJ, Argentina

Location

MeSH Terms

Interventions

dolutegravir; Lamivudine; Dual Anti-Platelet Therapy

Intervention Hierarchy (Ancestors)

Zalcitabine; Deoxycytidine; Cytidine; Pyrimidine Nucleosides; Pyrimidines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Deoxyribonucleosides; Nucleosides; Nucleic Acids, Nucleotides, and Nucleosides; Dideoxynucleosides; Drug Therapy, Combination; Drug Therapy; Therapeutics

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Scientific director

Study Record Dates

• First Submitted: October 25, 2019
• First Posted: March 25, 2022
• Study Start: May 22, 2019
• Primary Completion: August 1, 2022
• Study Completion: August 30, 2022
• Last Updated: April 12, 2022

Record last verified: 2022-04

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP, ICF, CSR
• Time Frame: 3 month after last patient last visit

Locations

AR (2)